JiMin Health: A subsidiary DB006 oncolytic adenovirus injection granted clinical trial approval.

Health Announcement: JIMIN Health Holding Subsidiary Hainan JIMIN Boao International Hospital Co., Ltd.'s DB006 Oncolytic Adenovirus Injection has received a drug clinical trial approval notification from the National Medical Products Administration. This drug is a gene therapy medication for the treatment of end-stage malignant solid tumors, previously obtained through patent and technology transfer from Guangzhou Dabo Bioproducts Co., Ltd.